Prof. Changyu Wang 王常玉
Chief Physician, Professor
Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gynecologic tumors and diseases, with expertise in complex surgeries, chemotherapy, fertility-sparing cervical cancer surgery, radical trachelectomy, and laparoscopic procedures for endometrial and cervical cancer.
Dr. Wang is a Chief Physician, Professor, and doctoral supervisor with 20 years of experience in clinical practice, teaching, and research. Dr. Wang manages the diagnosis and standardized treatment of malignant gynecologic tumors. Dr. Wang has led multiple National Natural Science Foundation projects, participated in provincial-level research, and co-authored obstetrics and gynecology textbooks.
Professional roles
- Member, Hubei Provincial Gynecologic Oncology Professional Committee
- Member, Wuhan Obstetrics and Gynecology Society
- Editorial Board Member, Tumor Prevention and Treatment Research
Name order: in Chinese the family name comes first (Wang Changyu). Papers usually list the name as Changyu Wang or Wang C.
Selected publications
51 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Med Sci, 2024 (senior author): High Expression of TBC1 Domain Family Member 22A is Related to Poor Prognosis in Ovarian Serous Cystadenocarcinoma. PubMed 39439452
- Genes (Basel), 2024 (senior author): Downregulation of RhoB Inhibits Cervical Cancer Progression and Enhances Cisplatin Sensitivity. PubMed 39336777
- Eur J Obstet Gynecol Reprod Biol, 2024 (senior author): Oncologic and reproductive outcomes after fertility-sparing surgery for bilateral borderline ovarian tumors: A retrospective study. PubMed 38422803
- J Gynecol Oncol, 2024 (senior author): Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia. PubMed 38216133
- Mol Carcinog, 2023 (senior author): A novel hypoxia-stimulated lncRNA HIF1A-AS3 binds with YBX1 to promote ovarian cancer tumorigenesis by suppressing p21 and AJAP1 transcription. PubMed 37589417
- Oncol Lett, 2023 (senior author): Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment. PubMed 37600330
- Curr Med Sci, 2023 (senior author): Is There Re-staging Surgery Necessity for Borderline Ovarian Tumors. PubMed 37455277
- Front Genet, 2023 (senior author): Low expression of acyl-CoA thioesterase 13 is associated with poor prognosis in ovarian serous cystadenocarcinoma. PubMed 37424730
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion